Condition

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma clinical trials and research

• 6Clinical trials
• 3Countries

Newest Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma clinical trials

All recruiting trials (6)

• Testing a B7‑H3 antibody–drug conjugate alone and with dostarlimab in recurrent/metastatic head and neck squamous cell carcinoma

  It tests an antibody–drug conjugate called GSK5764227 by itself or with the immunotherapy dostarlimab in adults with recurrent or metastatic head and neck squamous cell carcinoma who have received prior treatments.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07408063

• Iparomlimab and Tuvonralimab with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma

  This trial will test whether adding two immunotherapy drugs, iparomlimab and tuvonralimab, to cetuximab helps people with recurrent or metastatic head and neck squamous cell carcinoma who have already failed at least two prior systemic treatments.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07090317

• Sacituzumab Tirumotecan plus Toripalimab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

  This trial will test whether the antibody-drug conjugate sacituzumab tirumotecan combined with the PD-1 inhibitor toripalimab helps people with recurrent or metastatic head and neck squamous cell carcinoma whose tumors are Trop-2 positive and have PD-L1 CPS ≥1.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07088211

• SHR-A2102 with adebrelimab, with or without other anti-cancer drugs, for recurrent or metastatic head and neck squamous cell carcinoma

  This tests whether SHR-A2102 combined with adebrelimab, with or without other anti-cancer therapies, is safe and helps adults with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chongqing, Chongqing Municipality and 1 other locations · NCT07059221

• Combining dalpicilib with cetuximab for treating resistant head and neck cancer

  This study is testing if adding dalpicilib to cetuximab can help people with tough-to-treat head and neck cancer feel better compared to just using cetuximab alone.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT06935188

• Combining Pembrolizumab with Platinum and Gemcitabine for Head and Neck Cancer

  This study is testing if combining a drug called pembrolizumab with chemotherapy can help people with recurrent or advanced head and neck cancer feel better and live longer.

  Recruiting Phase 2 University of Malaya · Kuala Lumpur · NCT05286619

Related topics

Quick answers

How many Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in China (4 trials), Canada (1 trial), Malaysia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →